Premium
Plasmapheresis in neuroleptic malignant syndrome
Author(s) -
Gaitini L.,
Fradis M.,
Vaida S.,
Krimerman S.,
Beny A.
Publication year - 1997
Publication title -
anaesthesia
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.839
H-Index - 117
eISSN - 1365-2044
pISSN - 0003-2409
DOI - 10.1111/j.1365-2044.1997.11-az011.x
Subject(s) - plasmapheresis , medicine , neuroleptic malignant syndrome , dantrolene sodium , dantrolene , disease , anesthesia , surgery , immunology , antibody , calcium
Neuroleptic malignant syndrome is a severe and potentially fatal reaction to neuroleptic drugs. Treatment requires withdrawal of the neuroleptic agent, metabolic and cardiovascular support, physical cooling and treatment with dantrolene sodium and bromcriptine mesylate. We report a therapeutic success of plasmapheresis in a case of neuroleptic malignant syndrome in which conventional therapy had failed. We postulate that plasmapheresis may prove to be a useful tool in treating this frequently fatal disease.